Aquestive Therapeutics (AQST) News Today → [PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit Strategy (From DeFi Distribution) (Ad) Free AQST Stock Alerts $2.77 +0.02 (+0.73%) (As of 11:41 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 1:26 AM | americanbankingnews.comBrokers Issue Forecasts for Aquestive Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:AQST)June 7 at 1:26 AM | americanbankingnews.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.00 Consensus Price Target from AnalystsJune 6, 2024 | marketbeat.comArmistice Capital LLC Trims Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Armistice Capital LLC lessened its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 18.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,924,000 shares of the company's stock after selling 876,000 shJune 5, 2024 | americanbankingnews.comAquestive Therapeutics (NASDAQ:AQST) Given "Buy" Rating at HC WainwrightJune 5, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Wednesday.June 4, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of "Buy" by BrokeragesShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven brokerages that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buyJune 3, 2024 | globenewswire.comAquestive Therapeutics Announces Executive Appointments and Builds Commercial CapabilitiesMay 31, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Increase in Short InterestAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 6,180,000 shares, a growth of 17.3% from the April 30th total of 5,270,000 shares. Based on an average daily trading volume, of 2,840,000 shares, the short-interest ratio is currently 2.2 days.May 28, 2024 | finance.yahoo.comAquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy ConferenceMay 15, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings ResultsAquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.08). The firm had revenue of $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. During the same period last year, the firm posted $0.11 earnings per share.May 14, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Raised to "Strong-Buy" at Leerink PartnrsLeerink Partnrs raised shares of Aquestive Therapeutics to a "strong-buy" rating in a report on Friday.May 13, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Growth in Short InterestAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 5,270,000 shares, an increase of 31.4% from the April 15th total of 4,010,000 shares. Based on an average daily trading volume, of 2,810,000 shares, the days-to-cover ratio is presently 1.9 days.May 10, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price tMay 10, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Analysts at SVB LeerinkSVB Leerink began coverage on Aquestive Therapeutics in a research report on Friday. They issued an "outperform" rating and a $8.00 price target on the stock.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Solid Finances and Promising Anaphylm™ ProspectsMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Aquestive Therapeutics (NASDAQ:AQST)HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Thursday.May 9, 2024 | globenewswire.comAquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 9, 2024 | finance.yahoo.comAquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)May 8, 2024 | wsj.comAquestive Therapeutics Inc.May 7, 2024 | investorplace.comAQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | msn.comAquestive Therapeutics GAAP EPS of -$0.17, revenue of $12.05MMay 7, 2024 | globenewswire.comAquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 30, 2024 | markets.businessinsider.comAquestive Therapeutics Earns Buy Rating on Libervant’s Pediatric Approval and Anaphylm’s Market PotentialApril 30, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Aquestive Therapeutics (NASDAQ:AQST)HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday.April 29, 2024 | msn.comAquestive stock falls amid Libervant approval, Anaphylm updateApril 29, 2024 | finance.yahoo.comAquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual FilmApril 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Following FDA Approval and Growth ProspectsApril 26, 2024 | marketbeat.comShort Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Rises By 76.7%Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 4,010,000 shares, a growth of 76.7% from the March 31st total of 2,270,000 shares. Based on an average trading volume of 2,450,000 shares, the days-to-cover ratio is presently 1.6 days.April 25, 2024 | finance.yahoo.comAquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ETApril 17, 2024 | investorplace.comComing FDA Approvals Could Send These 3 Drug Stocks SoaringApril 12, 2024 | globenewswire.comAquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyApril 11, 2024 | msn.comPiper starts Aquestive at overweight, cites allergy reaction treatmentApril 11, 2024 | msn.comAquestive Therapeutics a new overweight at Piper on oral film productsApril 11, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Coverage Initiated by Analysts at Piper SandlerPiper Sandler initiated coverage on Aquestive Therapeutics in a research report on Thursday. They issued an "overweight" rating and a $10.00 price objective on the stock.April 5, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Friday.March 28, 2024 | marketbeat.comRaymond James Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST)Raymond James assumed coverage on Aquestive Therapeutics in a research report on Thursday. They set an "outperform" rating and a $7.00 price objective on the stock.March 25, 2024 | globenewswire.comAquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockMarch 25, 2024 | marketbeat.comLegato Capital Management LLC Makes New $688,000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Legato Capital Management LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 340,564 shares of the company's stock, valued at approMarch 20, 2024 | msn.comAquestive Therapeutics slumps 13%, prices $75M offeringMarch 20, 2024 | investorplace.comWhy Is Aquestive Therapeutics (AQST) Stock Down 14% Today?March 20, 2024 | insidertrades.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Alexander Mark Schobel Sells 50,000 SharesMarch 19, 2024 | globenewswire.comAquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common StockMarch 19, 2024 | finance.yahoo.comInsider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ...March 19, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Insider Sells $300,000.00 in StockAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $6.00, for a total transaction of $300,000.00. Following the transaction, the insider now owns 984,476 shares in the company, valued at $5,906,856. The sale was disclosed in a filing with the SEC, which is available through this link.March 19, 2024 | globenewswire.comAquestive Therapeutics Announces Proposed Public Offering of Common StockMarch 18, 2024 | marketbeat.comHC Wainwright Increases Aquestive Therapeutics (NASDAQ:AQST) Price Target to $9.00HC Wainwright boosted their price objective on shares of Aquestive Therapeutics from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Monday.March 18, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Decline in Short InterestAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 29th, there was short interest totalling 1,810,000 shares, a drop of 9.0% from the February 14th total of 1,990,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the short-interest ratio is presently 1.3 days. Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address [PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit Strategy (Ad)The crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially profit from this trillion-dollar niche WITHOUT buying a single coin, NFT or investing in ANYTHING. Grab the PDF here for free: AQST Media Mentions By Week AQST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.540.76▲Average Medical News Sentiment AQST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼93▲AQST Articles Average Week Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XERS News SCPH News OPTN News CMRX News FBIO News COLL News IRWD News SAVA News INVA News ELVN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored